These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 7104997

  • 21. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer.
    Cao S, Frank C, Shirasaka T, Rustum YM.
    Clin Cancer Res; 1995 Aug; 1(8):839-45. PubMed ID: 9816053
    [Abstract] [Full Text] [Related]

  • 22. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.
    Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH.
    Cancer Res; 1982 Feb; 42(2):450-6. PubMed ID: 6173112
    [Abstract] [Full Text] [Related]

  • 23. Incorporation of 5-fluorouracil into murine bone marrow DNA in vivo.
    Sawyer RC, Stolfi RL, Martin DS, Spiegelman S.
    Cancer Res; 1984 May; 44(5):1847-51. PubMed ID: 6713387
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. 5-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice.
    Zimmerman RJ, VanWinkle TJ, Mantel N, Frei E, Goldin A.
    Cancer Res; 1986 Feb; 46(2):694-700. PubMed ID: 3940636
    [Abstract] [Full Text] [Related]

  • 27. Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine.
    Ashour OM, Naguib FN, Panzica RP, Al Safarjalani ON, el Kouni MH.
    Biochem Pharmacol; 2000 Aug 01; 60(3):427-31. PubMed ID: 10856438
    [Abstract] [Full Text] [Related]

  • 28. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine.
    Darnowski JW, Handschumacher RE.
    Cancer Res; 1985 Nov 01; 45(11 Pt 1):5364-8. PubMed ID: 4053009
    [Abstract] [Full Text] [Related]

  • 29. Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid.
    Stolfi RL, Martin DS, Sawyer RC, Spiegelman S.
    Cancer Res; 1983 Feb 01; 43(2):561-6. PubMed ID: 6184150
    [Abstract] [Full Text] [Related]

  • 30. In vivo enhancement of 5-fluorouracil cytotoxicity to AKR leukemia cells by thymidine in mice.
    Santelli G, Valeriote F.
    J Natl Cancer Inst; 1978 Sep 01; 61(3):843-7. PubMed ID: 278862
    [Abstract] [Full Text] [Related]

  • 31. Intratumoral injection of thymidine: enhancement of the antitumor activity and incorporation of 5-fluorouracil into tumor RNA in a murine tumor system.
    Matsuoka H, Masuda H, Maehara Y, Sugimachi K, Inokuchi K.
    Cancer Treat Rep; 1986 Jul 01; 70(7):851-7. PubMed ID: 3719577
    [Abstract] [Full Text] [Related]

  • 32. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
    Sirotnak FM, Otter GM, Schmid FA.
    Cancer Res; 1993 Feb 01; 53(3):587-91. PubMed ID: 8425192
    [Abstract] [Full Text] [Related]

  • 33. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
    Ren Q, Van Groeningen CJ, Hardcastle A, Aherne GW, Geoffroy F, Allegra CJ, Johnston PG, Grem JL.
    Oncol Res; 1997 Feb 01; 9(2):77-88. PubMed ID: 9167189
    [Abstract] [Full Text] [Related]

  • 34. Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue. Correlation of antitumor activity with dosage and FUra incorporation into RNA.
    Nord LD, Stolfi RL, Martin DS.
    Biochem Pharmacol; 1992 Jun 23; 43(12):2543-9. PubMed ID: 1378737
    [Abstract] [Full Text] [Related]

  • 35. In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil.
    Peters GJ, van Dijk J, Laurensse E, van Groeningen CJ, Lankelma J, Leyva A, Nadal JC, Pinedo HM.
    Br J Cancer; 1988 Mar 23; 57(3):259-65. PubMed ID: 3355763
    [Abstract] [Full Text] [Related]

  • 36. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ, Moyer JD, Suffness M, Harrison SD, Cysyk R, Hamilton TC, Plowman J.
    Cancer Res; 1994 Feb 01; 54(3):724-9. PubMed ID: 8306334
    [Abstract] [Full Text] [Related]

  • 37. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
    Cao S, Troutt AB, Rustum YM.
    Cancer Res; 1998 Apr 15; 58(8):1695-9. PubMed ID: 9563485
    [Abstract] [Full Text] [Related]

  • 38. Enhancement by uridine of the anabolism of 5-fluorouracil in mouse T-lymphoma (S-49) cells.
    Parker WB, Klubes P.
    Cancer Res; 1985 Sep 15; 45(9):4249-56. PubMed ID: 2411399
    [Abstract] [Full Text] [Related]

  • 39. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
    Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Casper ES, Young CW.
    Cancer Res; 1983 May 15; 43(5):2317-21. PubMed ID: 6187448
    [Abstract] [Full Text] [Related]

  • 40. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity.
    van Groeningen CJ, Leyva A, Kraal I, Peters GJ, Pinedo HM.
    Cancer Treat Rep; 1986 Jun 15; 70(6):745-50. PubMed ID: 3731137
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.